0001437749-23-024680.txt : 20230825 0001437749-23-024680.hdr.sgml : 20230825 20230825161957 ACCESSION NUMBER: 0001437749-23-024680 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230807 FILED AS OF DATE: 20230825 DATE AS OF CHANGE: 20230825 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Anderson Thomas CENTRAL INDEX KEY: 0001612903 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36913 FILM NUMBER: 231208530 MAIL ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ZEVRA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001434647 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205894398 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103 CITY: CELEBRATION STATE: FL ZIP: 34747 BUSINESS PHONE: (321) 939-3416 MAIL ADDRESS: STREET 1: 1180 CELEBRATION BOULEVARD, SUITE 103 CITY: CELEBRATION STATE: FL ZIP: 34747 FORMER COMPANY: FORMER CONFORMED NAME: KEMPHARM, INC DATE OF NAME CHANGE: 20130530 FORMER COMPANY: FORMER CONFORMED NAME: KEMPHARM INC DATE OF NAME CHANGE: 20080507 4 1 rdgdoc.xml FORM 4 X0508 4 2023-08-07 0001434647 ZEVRA THERAPEUTICS, INC. ZVRA 0001612903 Anderson Thomas C/O ZEVRA THERAPEUTICS, INC. 1180 CELEBRATION BOULEVARD, SUITE 103 CELEBRATION FL 34747 1 0 Stock Option (right to buy) 4.86 2023-08-07 4 A 0 58800 0 A 2033-08-06 Common Stock 58800 58800 D The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, August 7, 2023. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. 33.33% of the total shares subject to the option vest in equal annual installments beginning one day prior to the date of the first annual meeting of the Issuer's stockholders following the day of grant and continuing for the next two annual meeting of the Issuer's stockholders, such that the option will be fully vested one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Thomas Anderson 2023-08-25